Get started
Author

Pinelopi Andrikakou

Observed name: Andrikakou, Pinelopi
ORCID: 0000-0002-3955-7995
Observed ORCID: 0000-0002-3955-7995
OpenAlex ID: A5064596541
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2020 · Debashis Sarker, Ruth Plummer, et al. · Clinical Cancer Research · 189
PDF
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer
2017 · Jon Voutila, Vikash Reebye, et al. · Molecular Therapy · 129
PDF
Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer
2018 · Vikash Reebye, Kai-Wen Huang, et al. · Oncogene · 109
PDF
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2021 · Ayumi Hashimoto, Debashis Sarker, et al. · Clinical Cancer Research · 103
On the behaviour of lung tissue under tension and compression
2016 · Pinelopi Andrikakou, Karthik Vickraman, et al. · Scientific Reports · 77
PDF
Targeted Delivery of C/EBPα-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC
2019 · Sorah Yoon, Kai-Wen Huang, et al. · Molecular Therapy — Nucleic Acids · 40
PDF
Enhancing SIRT1 Gene Expression Using Small Activating RNAs: A Novel Approach for Reversing Metabolic Syndrome
2022 · Pinelopi Andrikakou, Vikash Reebye, et al. · Nucleic Acid Therapeutics · 18
Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
2020 · Debashis Sarker, Mikael Sodergren, et al. · Journal of Clinical Oncology · 3
First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
2020 · Debashis Sarker, Mikael Sodergren, et al. · Journal of Clinical Oncology · 3
Abstract 1730: Up-regulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and cancer patients
2021 · Ayumi Hashimoto, Debashis Sarker, et al. · Cancer Research · 2
RNA activation as a precision dosing modality: MTL-CEBPA for controlled enzyme elevation in MPS I-H
2026 · Vikash Reebye, Konstantina Skourti-Stathaki, et al. · Frontiers in Medicine
RNA Activation of CEBPA in PBMCs Enhances α-L-Iduronidase Expression A Translational Adjuvant Therapy for MPS I After Bone Marrow Transplantation
2025 · Vikash Reebye, Konstantina S Stathaki, et al. · Research Square
PDF
Data from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024 · Ayumi Hashimoto, Debashis Sarker, et al.
Supplementary Table 3 from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024 · Ayumi Hashimoto, Debashis Sarker, et al.
Supplementary Table 2 from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024 · Ayumi Hashimoto, Debashis Sarker, et al.
Supplementary Data from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024 · Ayumi Hashimoto, Debashis Sarker, et al.
Supplementary Table 1 from Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
2024 · Ayumi Hashimoto, Debashis Sarker, et al.
Supplementary Legends from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2023 · Debashis Sarker, Ruth Plummer, et al.
Supplementary Tables from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2023 · Debashis Sarker, Ruth Plummer, et al.
Appendix A from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2023 · Debashis Sarker, Ruth Plummer, et al.
PDF
Supplementary Figure 2 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2023 · Debashis Sarker, Ruth Plummer, et al.
Supplementary Figure 5 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2023 · Debashis Sarker, Ruth Plummer, et al.
Supplementary Figure 4 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2023 · Debashis Sarker, Ruth Plummer, et al.
Supplementary Figure 1 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2023 · Debashis Sarker, Ruth Plummer, et al.
Supplementary Figure 3 from MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
2023 · Debashis Sarker, Ruth Plummer, et al.
Works count: 30
Citation count: 673
H-index: 7
I10-index: 7
Year
Topic
Type